X0609 4 2026-09-17 0 0001743881 BridgeBio Pharma, Inc. BBIO 0001742485 Kumar Neil false C/O BRIDGEBIO PHARMA, INC. 3160 PORTER DR., SUITE 250 PALO ALTO CA 94304 1 1 0 0 Chief Executive Officer 1 Common Stock 2026-09-17 4 S 0 8721 69.0136 D 496965 I By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee. Common Stock 2026-09-17 4 S 0 1279 69.5696 D 495686 I By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee. Common Stock 3568447 I By Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee. Common Stock 750000 I By NK 2026 GRAT Common Stock 243327 D This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on May 13, 2026. Represents the weighted average sale price of the shares sold from $68.52 to $69.40 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose. Represents the weighted average sale price of the shares sold from $69.525 to $69.64 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote. These shares are held by the NK 2026 GRAT, a grantor retained annuity trust of which the Reporting Person is the sole trustee and sole annuitant. The Reporting Person disclaims beneficial ownership of the shares held by the NK 2026 GRAT except to the extent of his pecuniary interest therein. /s/ Will Solis, Attorney-in-Fact 2026-09-21